Alessandro Aiuti MD, PhD

Dr. Alessandro Aiuti has a strong background in immunology and hematology and has been involved since many years in studying the genetics, disease pathogenesis and innovative treatments of several congenital immunological defects (such as ADA-SCID, DADA2, ARPC1B, X-CGD, Wiskott-Aldrich Syndrome, Ataxia Teleangectasia, CVID, DiGeorge Syndrome). He is part of the international COVID-HGE consortium that is studying the genetic and immunological bases of susceptibility to severe COVID-19 disease. Dr. Aiuti is author of more than 230 publications in international scientific peer-reviewed journals and contributed 8 book chapters. He gave more than 100 lectures as invited speaker and abstract presentations to national and international congresses in the last 5 years.

He is Member (representing clinicians) of the Committee for Advanced Therapies (CAT) of the European Medicines Agency (EMA). He is board member of IPINET and ESGCT, member of: the Inborn Errors Working Party (IEWP), ASGCT (International Committee and Global Outreach Committee), European Reference Network (ERN) on Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases Network (RITA). He serves as reviewer for: Nature, NEJM, Blood, Hum Gen Ther, Haematologica, JACI, Mol Ther, Frontiers. Dr. Aiuti’s research is funded by international and national agencies including the European Union, Telethon Foundation, the Italian Ministry of Education University and Research, Italian Ministry of Health, Else Kroener Fresenius Foundation.